In their second collaboration in a span of almost three years, Zai Lab has entered into an agreement with MacroGenics to develop and commercialise preclinical bispecific antibodies in oncology. The agreement involves four immuno-oncology programmes in which Zai Lab grants a combination of regional Asian and global rights. In return, Zai Lab receives rights to MacroGenics dual-affinity re-targeting (DART®) and TRIDENT multi-specific platforms along with a lead research programme targeting solid tumours. The deal aligns with Zai Lab’s strategy to expand its oncology portfolio by seeking partnership in therapies for China and across the world.